Brevan Howard Capital Management LP Arcutis Biotherapeutics, Inc. Transaction History
Brevan Howard Capital Management LP
- $9.23 Billion
- Q1 2025
A detailed history of Brevan Howard Capital Management LP transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 40,618 shares of ARQT stock, worth $584,899. This represents 0.01% of its overall portfolio holdings.
Number of Shares
40,618Holding current value
$584,899% of portfolio
0.01%Shares
4 transactions
Others Institutions Holding ARQT
# of Institutions
252Shares Held
126MCall Options Held
605KPut Options Held
170K-
Suvretta Capital Management, LLC New York, NY11.4MShares$164 Million7.82% of portfolio
-
Jennison Associates LLC11.4MShares$164 Million0.13% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$158 Million4.91% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$127 Million8.65% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$124 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $867M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...